Annual SG&A
$937.30 M
+$83.30 M+9.75%
31 December 2023
Summary:
BioMarin Pharmaceutical annual selling, general & administrative expenses is currently $937.30 million, with the most recent change of +$83.30 million (+9.75%) on 31 December 2023. During the last 3 years, it has risen by +$199.60 million (+27.06%). BMRN annual SG&A is now at all-time high.BMRN Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$253.48 M
-$9.55 M-3.63%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly selling, general & administrative expenses is currently $253.48 million, with the most recent change of -$9.55 million (-3.63%) on 30 September 2024. Over the past year, it has increased by +$29.48 million (+13.16%). BMRN quarterly SG&A is now -7.83% below its all-time high of $275.00 million, reached on 31 December 2023.BMRN Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.90 B
+$322.29 M+14.50%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM selling, general & administrative expenses is currently -$1.90 billion, with the most recent change of +$322.29 million (+14.50%) on 30 September 2024. Over the past year, it has dropped by -$2.79 billion (-314.22%). BMRN TTM SG&A is now -9592.87% below its all-time high of $1.02 billion, reached on 30 September 2024.BMRN TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +9.8% | +13.2% | -314.2% |
| 3 y3 years | +27.1% | +38.3% | -357.7% |
| 5 y5 years | +55.1% | +49.0% | -389.1% |
BMRN Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +27.1% | -7.8% | +38.3% | at high | +45.3% |
| 5 y | 5 years | at high | +55.1% | -7.8% | +49.0% | at high | +72.9% |
| alltime | all time | at high | >+9999.0% | -7.8% | >+9999.0% | -9592.9% | +72.9% |
BioMarin Pharmaceutical Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $253.48 M(-3.6%) | $1.02 B(+3.0%) |
| June 2024 | - | $263.03 M(+16.4%) | $987.94 M(+6.1%) |
| Mar 2024 | - | $225.91 M(-17.9%) | $931.01 M(+1.6%) |
| Dec 2023 | $937.30 M(+9.8%) | $275.00 M(+22.8%) | $916.13 M(+3.3%) |
| Sept 2023 | - | $224.00 M(+8.7%) | $886.83 M(+0.8%) |
| June 2023 | - | $206.10 M(-2.3%) | $879.63 M(+1.1%) |
| Mar 2023 | - | $211.02 M(-14.1%) | $870.36 M(+1.9%) |
| Dec 2022 | $854.00 M(+12.5%) | $245.70 M(+13.3%) | $853.95 M(+3.4%) |
| Sept 2022 | - | $216.80 M(+10.1%) | $825.85 M(+4.2%) |
| June 2022 | - | $196.84 M(+1.1%) | $792.35 M(+1.6%) |
| Mar 2022 | - | $194.62 M(-10.6%) | $779.72 M(+2.7%) |
| Dec 2021 | $759.40 M(+2.9%) | $217.60 M(+18.7%) | $759.40 M(+3.0%) |
| Sept 2021 | - | $183.30 M(-0.5%) | $737.30 M(+0.5%) |
| June 2021 | - | $184.20 M(+5.7%) | $733.50 M(+1.2%) |
| Mar 2021 | - | $174.30 M(-10.8%) | $724.70 M(-1.8%) |
| Dec 2020 | $737.70 M(+8.3%) | $195.50 M(+8.9%) | $737.70 M(+1.0%) |
| Sept 2020 | - | $179.50 M(+2.3%) | $730.08 M(+1.3%) |
| June 2020 | - | $175.40 M(-6.4%) | $720.69 M(+2.1%) |
| Mar 2020 | - | $187.30 M(-0.3%) | $705.99 M(+3.7%) |
| Dec 2019 | $680.90 M(+12.7%) | $187.88 M(+10.4%) | $680.85 M(+3.6%) |
| Sept 2019 | - | $170.11 M(+5.9%) | $657.19 M(+3.4%) |
| June 2019 | - | $160.70 M(-0.9%) | $635.64 M(+1.2%) |
| Mar 2019 | - | $162.16 M(-1.3%) | $628.22 M(+3.9%) |
| Dec 2018 | $604.40 M(+9.0%) | $164.22 M(+10.5%) | $604.40 M(+0.7%) |
| Sept 2018 | - | $148.57 M(-3.1%) | $600.46 M(+3.1%) |
| June 2018 | - | $153.28 M(+10.8%) | $582.43 M(+1.7%) |
| Mar 2018 | - | $138.34 M(-13.7%) | $572.65 M(+3.3%) |
| Dec 2017 | $554.34 M(+16.3%) | $160.28 M(+22.8%) | $554.34 M(+3.2%) |
| Sept 2017 | - | $130.53 M(-9.0%) | $537.01 M(+2.2%) |
| June 2017 | - | $143.50 M(+19.6%) | $525.24 M(+6.9%) |
| Mar 2017 | - | $120.02 M(-16.0%) | $491.31 M(+3.1%) |
| Dec 2016 | $476.59 M(+18.5%) | $142.96 M(+20.4%) | $476.59 M(+6.5%) |
| Sept 2016 | - | $118.76 M(+8.4%) | $447.54 M(+5.8%) |
| June 2016 | - | $109.58 M(+4.1%) | $422.83 M(+1.9%) |
| Mar 2016 | - | $105.30 M(-7.6%) | $414.76 M(+3.1%) |
| Dec 2015 | $402.27 M(+33.1%) | $113.91 M(+21.1%) | $402.27 M(+3.6%) |
| Sept 2015 | - | $94.04 M(-7.4%) | $388.13 M(+5.3%) |
| June 2015 | - | $101.51 M(+9.4%) | $368.69 M(+10.0%) |
| Mar 2015 | - | $92.81 M(-7.0%) | $335.27 M(+10.8%) |
| Dec 2014 | $302.16 M(+28.4%) | $99.77 M(+33.7%) | $302.53 M(+10.2%) |
| Sept 2014 | - | $74.60 M(+9.6%) | $274.57 M(+4.9%) |
| June 2014 | - | $68.09 M(+13.4%) | $261.81 M(+7.1%) |
| Mar 2014 | - | $60.07 M(-16.3%) | $244.38 M(+3.8%) |
| Dec 2013 | $235.36 M(+18.8%) | $71.81 M(+16.1%) | $235.36 M(+7.7%) |
| Sept 2013 | - | $61.84 M(+22.1%) | $218.60 M(+7.6%) |
| June 2013 | - | $50.66 M(-0.8%) | $203.09 M(-0.4%) |
| Mar 2013 | - | $51.05 M(-7.3%) | $203.97 M(+2.9%) |
| Dec 2012 | $198.17 M(+13.0%) | $55.05 M(+18.8%) | $198.17 M(+3.4%) |
| Sept 2012 | - | $46.34 M(-10.1%) | $191.58 M(+0.8%) |
| June 2012 | - | $51.54 M(+13.9%) | $190.12 M(+5.9%) |
| Mar 2012 | - | $45.25 M(-6.6%) | $179.60 M(+2.4%) |
| Dec 2011 | $175.42 M | $48.45 M(+8.0%) | $175.39 M(+3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $44.88 M(+9.4%) | $169.03 M(+4.0%) |
| June 2011 | - | $41.02 M(-0.1%) | $162.50 M(+2.4%) |
| Mar 2011 | - | $41.04 M(-2.5%) | $158.76 M(+4.6%) |
| Dec 2010 | $151.72 M(+22.1%) | $42.10 M(+9.8%) | $151.72 M(+3.8%) |
| Sept 2010 | - | $38.35 M(+2.9%) | $146.15 M(+7.1%) |
| June 2010 | - | $37.28 M(+9.6%) | $136.47 M(+5.2%) |
| Mar 2010 | - | $34.00 M(-6.9%) | $129.72 M(+4.4%) |
| Dec 2009 | $124.29 M(+16.6%) | $36.53 M(+27.4%) | $124.29 M(+6.7%) |
| Sept 2009 | - | $28.67 M(-6.1%) | $116.49 M(-0.3%) |
| June 2009 | - | $30.53 M(+6.9%) | $116.79 M(+4.8%) |
| Mar 2009 | - | $28.57 M(-0.6%) | $111.47 M(+4.6%) |
| Dec 2008 | $106.57 M(+37.4%) | $28.73 M(-0.8%) | $106.57 M(+4.2%) |
| Sept 2008 | - | $28.96 M(+14.9%) | $102.30 M(+10.2%) |
| June 2008 | - | $25.20 M(+6.5%) | $92.86 M(+8.9%) |
| Mar 2008 | - | $23.67 M(-3.2%) | $85.30 M(+9.5%) |
| Dec 2007 | $77.54 M(+58.1%) | $24.46 M(+25.3%) | $77.89 M(+15.6%) |
| Sept 2007 | - | $19.52 M(+10.6%) | $67.40 M(+12.0%) |
| June 2007 | - | $17.65 M(+8.6%) | $60.17 M(+10.6%) |
| Mar 2007 | - | $16.26 M(+16.4%) | $54.39 M(+10.9%) |
| Dec 2006 | $49.03 M(+18.0%) | $13.97 M(+13.7%) | $49.03 M(+6.3%) |
| Sept 2006 | - | $12.29 M(+3.5%) | $46.13 M(+5.7%) |
| June 2006 | - | $11.87 M(+8.9%) | $43.64 M(+4.2%) |
| Mar 2006 | - | $10.90 M(-1.6%) | $41.89 M(+0.8%) |
| Dec 2005 | $41.56 M(+10.5%) | $11.08 M(+13.1%) | $41.56 M(-5.1%) |
| Sept 2005 | - | $9.80 M(-3.2%) | $43.78 M(-6.3%) |
| June 2005 | - | $10.12 M(-4.3%) | $46.75 M(+5.8%) |
| Mar 2005 | - | $10.57 M(-20.6%) | $44.17 M(+17.8%) |
| Dec 2004 | $37.61 M(+161.2%) | $13.30 M(+4.2%) | $37.48 M(+26.4%) |
| Sept 2004 | - | $12.76 M(+69.3%) | $29.66 M(+59.8%) |
| June 2004 | - | $7.54 M(+94.3%) | $18.56 M(+19.9%) |
| Mar 2004 | - | $3.88 M(-29.1%) | $15.48 M(+7.5%) |
| Dec 2003 | $14.40 M(-14.7%) | $5.47 M(+229.4%) | $14.40 M(-3.1%) |
| Sept 2003 | - | $1.66 M(-62.7%) | $14.86 M(-13.3%) |
| June 2003 | - | $4.46 M(+59.3%) | $17.14 M(+8.9%) |
| Mar 2003 | - | $2.80 M(-52.9%) | $15.74 M(-6.7%) |
| Dec 2002 | $16.87 M(+164.0%) | $5.94 M(+50.8%) | $16.87 M(+71.9%) |
| Sept 2002 | - | $3.94 M(+28.7%) | $9.81 M(+10.7%) |
| June 2002 | - | $3.06 M(-22.0%) | $8.87 M(+20.8%) |
| Mar 2002 | - | $3.93 M(-452.4%) | $7.34 M(+50.2%) |
| Dec 2001 | $6.39 M(-1.8%) | -$1.11 M(-137.2%) | $4.89 M(-18.4%) |
| Sept 2001 | - | $2.99 M(+94.9%) | $5.99 M(+12.4%) |
| June 2001 | - | $1.54 M(+4.2%) | $5.33 M(-10.9%) |
| Mar 2001 | - | $1.47 M(<-9900.0%) | $5.99 M(-8.0%) |
| Dec 2000 | $6.51 M(+36.8%) | -$10.00 K(-100.4%) | $6.51 M(+0.5%) |
| Sept 2000 | - | $2.33 M(+6.4%) | $6.47 M(+5.4%) |
| June 2000 | - | $2.19 M(+9.7%) | $6.14 M(+21.6%) |
| Mar 2000 | - | $2.00 M(-4741.9%) | $5.05 M(+6.4%) |
| Dec 1999 | $4.76 M(+35.9%) | -$43.00 K(-102.2%) | $4.75 M(-0.9%) |
| Sept 1999 | - | $2.00 M(+81.8%) | $4.79 M(+71.6%) |
| June 1999 | - | $1.10 M(-35.0%) | $2.79 M(+65.0%) |
| Mar 1999 | - | $1.69 M | $1.69 M |
| Dec 1998 | $3.50 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual selling, general & administrative expenses?
- What is the all time high annual SG&A for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual SG&A year-on-year change?
- What is BioMarin Pharmaceutical quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly SG&A year-on-year change?
- What is BioMarin Pharmaceutical TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM SG&A year-on-year change?
What is BioMarin Pharmaceutical annual selling, general & administrative expenses?
The current annual SG&A of BMRN is $937.30 M
What is the all time high annual SG&A for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual selling, general & administrative expenses is $937.30 M
What is BioMarin Pharmaceutical annual SG&A year-on-year change?
Over the past year, BMRN annual selling, general & administrative expenses has changed by +$83.30 M (+9.75%)
What is BioMarin Pharmaceutical quarterly selling, general & administrative expenses?
The current quarterly SG&A of BMRN is $253.48 M
What is the all time high quarterly SG&A for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly selling, general & administrative expenses is $275.00 M
What is BioMarin Pharmaceutical quarterly SG&A year-on-year change?
Over the past year, BMRN quarterly selling, general & administrative expenses has changed by +$29.48 M (+13.16%)
What is BioMarin Pharmaceutical TTM selling, general & administrative expenses?
The current TTM SG&A of BMRN is -$1.90 B
What is the all time high TTM SG&A for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM selling, general & administrative expenses is $1.02 B
What is BioMarin Pharmaceutical TTM SG&A year-on-year change?
Over the past year, BMRN TTM selling, general & administrative expenses has changed by -$2.79 B (-314.22%)